Collegium Pharmaceutical (NASDAQ:COLL) Cut to “Hold” at Wall Street Zen

Posted by George Bondi on Aug 11th, 2026

Wall Street Zen cut shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) from a buy rating to a hold rating in a research report released on Saturday morning.

Other research analysts have also recently issued reports about the company. Needham & Company LLC lowered their price objective on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Weiss Ratings restated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $52.60.

View Our Latest Research Report on Collegium Pharmaceutical

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $27.20 on Friday. The stock has a market cap of $885.63 million, a P/E ratio of 21.94 and a beta of 0.73. The company has a fifty day simple moving average of $34.69 and a 200-day simple moving average of $36.87. Collegium Pharmaceutical has a 12-month low of $27.11 and a 12-month high of $50.79. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last issued its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.68 earnings per share. Equities analysts expect that Collegium Pharmaceutical will post 6.76 EPS for the current fiscal year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Large investors have recently bought and sold shares of the stock. NewEdge Wealth LLC purchased a new position in shares of Collegium Pharmaceutical during the second quarter worth about $1,773,000. BlackRock Inc. purchased a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $196,972,000. Deutsche Bank AG purchased a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $1,270,000. Bank of New York Mellon Corp purchased a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $8,506,000. Finally, State of Wyoming acquired a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at about $218,000.

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.